Formaat : 200mg
Synonyms: Stilbestrol, DES
| Description | Diethylstilbestrol (DES) is used in the treatment of menopausal and postmenopausal disorders. |
| In vitro | Diethylstilbestrol promotes coactivator release from orphan nuclear receptor ERR beta and inhibits its transcriptional activity in trophoblast stem cells. [1] |
| In vivo | Diethylstilbestrol treated pregnant mice exhibits abnormal early placenta development associated with an overabundance of trophoblast giant cells and an absence of diploid trophoblast. [1] Diethylstilbestrol causes epigenetic methylation changes that result in persistent alterations in gene expression, leading to tumorigenesis in mouse uterus. Diethylstilbestrol induces c-fos exon-4 hypomethylation at postnatal day 17 in mice uterus, while elevating its mRNA level from postnatal day 5. Diethylstilbestrol exposure leads to hypomethylation in the exon-4 region of c-fos mRNA. [2] Diethylstilbestrol-treated rats exhibits more pronounced delay in maturational development of an adult pattern of immunoexpression of the three proteins compared with GnRHa-treated rats. Diethylstilbestrol results in similar reductions in both Sertoli cell numbers and suppression of testicular growth at 18 and 25 days, though by 35 days the suppression is more pronounced in DES-treated rats. [3] Diethylstilbestrol treatment appears to imprint an abnormal, site-specific demethylation of CpG/-464, which requires ovarian hormones to occur in adult mice. [4] Diethylstilbestrol (2.0 ng/g) per day increases adult prostate weight, whereas a 200 ng/g dose decreases adult prostate weight in male offspring mice. [5] |
| Synonyms | Stilbestrol, DES |
| Molecular Weight | 268.35 |
| Formula | C18H20O2 |
| Cas No. | 56-53-1 |
| Smiles | CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1 |
| Relative Density. | 1.1096 g/cm3 (Estimated) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (372.65 mM), Sonication is recommended.  Ethanol: 50 mg/mL (186.32 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (37.26 mM), Solution. 10% DMSO+90% Saline: < 10 mg/mL (37.26 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
